| |
|
|
|
|
|
|
|||
|
Blood, 8 January 2009, Vol. 113, No. 2, pp. 291-298. Prepublished online as a Blood First Edition Paper on August 14, 2008; DOI 10.1182/blood-2008-04-153239.
Submitted April 29, 2008
Hematology, Erasmus University Medical Center, Rotterdam, Netherlands * Corresponding author; email: b.wouters{at}erasmusmc.nl.
The past decade has shown a marked increase in the use of high-throughput assays in clinical research into human cancer, including acute myeloid leukemia (AML). In particular, genome-wide gene expression profiling (GEP) using DNA microarrays has been extensively used for improved understanding of the diagnosis, prognosis and pathobiology of this heterogeneous disease. This review discusses the progress that has been made, it places the technological limitations in perspective, and highlights promising future avenues.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2008 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||